Approximately 90% of ERα-positive patients are also AR-positive (AR+) [117], and this is associated with favorable prognosis i.e., longer relapse-free survival, response to therapy, older age at diagnosis, lower tumor grade, lower Ki67 positivity and smaller tumor size [118,119,120]. Here, ESR1 is linked to neoplasm.